Merck (MRK) earnings Q3 2025

Merck on Thursday reported third-quarter earnings and income that topped estimates because it noticed sturdy demand for its most cancers immunotherapy Keytruda.

The drugmaker additionally narrowed its full-year revenue outlook to mirror decrease estimated tariff prices, amongst different components. Shares of Merck closed flat on Thursday.

Gross sales of Keytruda topped $8 billion for the primary time in 1 / 4, rising 10% from the identical interval a yr in the past. Income from the drug of $8.14 billion got here in simply just below the $8.24 billion analysts had been anticipating, based on StreetAccount estimates. 

The outcomes come as Merck slashes $3 billion in prices by the top of 2027, and prepares to offset income losses from the upcoming patent expiration of Keytruda in 2028.

The pharmaceutical big now expects its 2025 adjusted earnings to return in between $8.93 and $8.98 per share. That compares with its earlier outlook of $8.87 to $8.97.

Merck stated that displays a number of new objects, together with “decrease estimated prices associated to the affect of tariffs.” Throughout the earlier two quarters, the corporate included a $200 million estimated hit from tariffs that President Donald Trump has carried out so far, however not his deliberate pharmaceutical-specific levies. Merck didn’t disclose a brand new estimate for the price of current tariffs. 

Merck stated the steerage additionally displays a profit from an amended cope with AstraZeneca associated to a tablet for a selected genetic dysfunction, partially offset by prices tied to the corporate’s now-completed acquisition of Verona Pharma. 

Merck expects income for the yr to return in between $64.5 billion and $65 billion, narrowed on each ends from its earlier steerage of $64.3 billion to $65.3 billion. 

Here is what Merck reported for the third quarter in contrast with what Wall Road was anticipating, primarily based on a survey of analysts by LSEG: 

• Earnings per share: $2.58 adjusted vs. $2.35 anticipated
• Income: $17.28 billion vs. $16.96 billion anticipated

The corporate posted internet earnings of $5.79 billion, or $2.32 per share, for the quarter. That compares with internet earnings of $3.16 billion, or $1.24 per share, for the year-earlier interval. 

Excluding acquisition and restructuring prices, Merck earned $2.58 per share for the third quarter.

Merck raked in $17.28 billion in income for the quarter, up 4% from the identical interval a yr in the past.

Merck continued to see hassle with China gross sales of Gardasil, a vaccine that forestalls most cancers from HPV, the commonest sexually transmitted an infection within the U.S.

In February, Merck introduced a choice to halt shipments of Gardasil into China starting that month. In July, CFO Caroline Litchfield stated the corporate is not going to resume shipments to China by means of at the very least the top of 2025, noting that inventories stay excessive and demand remains to be tender.

Gardasil generated gross sales of $1.75 billion for the quarter, down 24% from the identical interval a yr in the past because of decrease demand in China. Nonetheless, that was in keeping with what analysts had been anticipating, based on StreetAccount.

Buyers are keen for added updates on Gardasil’s presence in China and any particulars from Merck on potential drug pricing offers with Trump as a part of his controversial “most favored nation” coverage. Trump has to this point inked agreements with Pfizer, AstraZeneca and EMD Serono, the most important fertility drug producer on the earth, that intention to make their medicines simpler for People to entry.

In an earnings name on Thursday, Merck CEO Rob Davis stated the corporate shares the Trump administration’s aim of “lowering affected person out-of-pocket prices for our merchandise within the U.S. whereas on the similar time realizing larger costs for our medicines and vaccines in international locations that haven’t been paying truthful worth for the innovation we offer.” 

Merck is “actively engaged” with the administration to attain these efforts. 

Merck’s pharmaceutical unit, which develops a variety of medication, booked $15.61 billion in income through the third quarter. That is up 4% from the identical interval a yr earlier.

The rise in Keytruda was pushed by greater uptake of the drug for earlier-stage cancers and robust demand for the therapy for metastatic cancers, which unfold to different elements of the physique, the corporate stated.

In the meantime, Merck’s newer drug Winrevair, which is used to deal with a uncommon, lethal lung situation, recorded $360 million in gross sales for the quarter. Analysts had anticipated the treatment to herald $413 million, based on StreetAccount estimates. 

Winrevair’s progress largely displays greater uptake within the U.S. But it surely was partially offset by the timing of distributor purchases of the drug and decrease internet pricing within the nation, primarily because of modifications to Medicare prescription drug plans. 

Merck’s animal well being division, which develops vaccines and medicines for canine, cats and cattle, posted almost $1.62 billion in gross sales, up 9% from the identical interval a yr prior. The corporate stated that primarily displays greater demand for livestock merchandise.

Correction: Gross sales for Merck’s animal well being division had been up 9% from the identical interval a yr prior. An earlier model misstated the proportion.